30 September 2019
Canberra, ACT
The nation’s peak body for generic and biosimilar medicines, the Generic and Biosimilar Medicines Association (GBMA), is delighted to announce Ms Lisa Golden’s appointment as the organisation’s newest Board director.
Ms Golden has more than 15 years commercial pharmaceutical experience and was recently appointed to the newly created role of Chief Commercial Officer for Arrotex Pharmaceuticals, responsible for commercial strategy and implementation.
The GBMA Chief Executive Officer, Ms Marnie Peterson, welcomed Ms Golden’s appointment, saying her experience in the pharmaceutical sector was a valuable asset to the GBMA Board.
Ms Golden is very well known and well respected within the industry. Having spent the last six years at an executive level in both generic and branded pharmaceuticals, she has been responsible for shaping, influencing and implementing business strategy and the broader industry landscape.
“The wealth of knowledge and experience that Ms Golden brings to the table is a huge benefit to the GBMA and we are delighted with her appointment to the Board.” Ms Peterson said.
Ms Golden joins the GBMA Board at an important time. The sustainability of the health system has never been more important, and generic and biosimilar medicines play a critically important role in the future of Australia’s healthcare system and underpinning the viability of the PBS.
Ms Golden will represent Apotex on the GBMA Board and Arrow will continue to be represented by its CEO, Mr Dennis Bastas.
Whilst having merged as Arrotex this year, both Apotex and Arrow will remain as separate entities, with individual representation at the Board level.
The GBMA Board is comprised of highly experienced generic and biosimilar pharmaceutical industry executives, who are collectively committed to delivering high value, high quality medicines to Australian patients, ensuring all Australians receive the best health outcomes today and into the future.
The Generic and Biosimilar Medicines Association Executive Board
Mr Sylvain Vigneault (Chair), Mylan Australia
Mr Mark Crotty (Deputy Chair), Juno Pharmaceuticals
Mr Guy Strong, Sandoz Australia
Mr Dennis Bastas, Arrow Pharmaceuticals
Ms Lisa Golden, Apotex Australia
Dr Neill Stacey, Southern Cross Pharma
–ENDS–
ABOUT GBMA
The GBMA is the national association representing companies that manufacture, supply and export generic and biosimilar medicines. GBMA represents all major generic medicine suppliers in Australia, accounting for more than 90% of all generic medicines dispensed in Australia. Members of GBMA ensure all Australians are offered high quality generic and biosimilar medicines, which provide affordable health outcomes that benefit all Australians. Members of GBMA take seriously their role in the responsible provision of affordable medicines in Australia, as stipulated in the National Medicines Policy. The generic and biosimilar medicines sector is a high value-add sector delivering significant health and economic benefits to the Australian public. The availability of generic medicines in this country helps to deliver:
– Timely access to affordable medicines;
– Substantial savings to the PBS;
– Thousands of highly skilled jobs; and
– Domestic manufacturing and annual exports of around $300 million.
For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au
–ENDS–
